Real-World Treatment Patterns in Men with Castration- Resistant Prostate Cancer Receiving Docetaxel
**Background:** Docetaxel has been a standard of care for castration-resistant prostate cancer (CRPC) in the United States since 2004, yet little has been reported on its patterns of use in routine practice. To help understand these patterns, a retrospective study was conducted and is reported here....
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Columbia Data Analytics, LLC
2015-01-01
|
| Series: | Journal of Health Economics and Outcomes Research |
| Online Access: | https://doi.org/10.36469/9894 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|